Lv5
1018 积分 2023-12-07 加入
Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy—What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?
3天前
已完结
Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in Men with High-Risk Biochemically Recurrent Prostate Cancer and Prior Radiotherapy: EMBARK Subgroup Analysis
22天前
已完结
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial
23天前
已完结
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
2个月前
已完结
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
4个月前
已完结
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
5个月前
已关闭
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
6个月前
已完结
New perspectives for targeting therapy in ALK-positive human cancers
6个月前
已完结
Prostate cancer
7个月前
已完结
Prostate cancer
8个月前
已完结
皖公网安备34019202002308
